Association of severe and fatal infections and treatment with pentostatin

P. J. O'Dwyer, A. S D Spiers, S. Marsoni

Research output: Contribution to journalArticle

Abstract

Pentostatin (dCF), an inhibitor of adenosine deaminase, has shown activity in the treatment of several lymphoid malignancies, even in the earliest phase I trials. An analysis of the first 300 patients treated in such trials shows a high incidence of severe infection (8%) during the relatively brief period of treatment. Of 24 patients in whom infection was diagnosed, 17 had no evidence of myelosuppression. The causative organisms included viruses, fungi, and bacteria of both high and low pathogenicity. Two-thirds of the infections were fatal. It is suggested that dCF may cause a syndrome similar to severe combined immunodeficiency during the course of treatment. Patients treated with dCF who show evidence of infection, even in the absence of neutropenia, should receive vigorous and rapid diagnostic evaluation to establish the cause of their infection, and aggressive treatment of suspected organisms.

Original languageEnglish
Pages (from-to)1117-1120
Number of pages4
JournalCancer Treatment Reports
Volume70
Issue number9
Publication statusPublished - 1986

Fingerprint

Pentostatin
Infection
Adenosine Deaminase Inhibitors
Therapeutics
Severe Combined Immunodeficiency
Neutropenia
Virulence
Fungi
Viruses
Bacteria
Incidence
Neoplasms

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

O'Dwyer, P. J., Spiers, A. S. D., & Marsoni, S. (1986). Association of severe and fatal infections and treatment with pentostatin. Cancer Treatment Reports, 70(9), 1117-1120.

Association of severe and fatal infections and treatment with pentostatin. / O'Dwyer, P. J.; Spiers, A. S D; Marsoni, S.

In: Cancer Treatment Reports, Vol. 70, No. 9, 1986, p. 1117-1120.

Research output: Contribution to journalArticle

O'Dwyer, PJ, Spiers, ASD & Marsoni, S 1986, 'Association of severe and fatal infections and treatment with pentostatin', Cancer Treatment Reports, vol. 70, no. 9, pp. 1117-1120.
O'Dwyer, P. J. ; Spiers, A. S D ; Marsoni, S. / Association of severe and fatal infections and treatment with pentostatin. In: Cancer Treatment Reports. 1986 ; Vol. 70, No. 9. pp. 1117-1120.
@article{de7640fa2dcb4d0399a728d6a436f8f9,
title = "Association of severe and fatal infections and treatment with pentostatin",
abstract = "Pentostatin (dCF), an inhibitor of adenosine deaminase, has shown activity in the treatment of several lymphoid malignancies, even in the earliest phase I trials. An analysis of the first 300 patients treated in such trials shows a high incidence of severe infection (8{\%}) during the relatively brief period of treatment. Of 24 patients in whom infection was diagnosed, 17 had no evidence of myelosuppression. The causative organisms included viruses, fungi, and bacteria of both high and low pathogenicity. Two-thirds of the infections were fatal. It is suggested that dCF may cause a syndrome similar to severe combined immunodeficiency during the course of treatment. Patients treated with dCF who show evidence of infection, even in the absence of neutropenia, should receive vigorous and rapid diagnostic evaluation to establish the cause of their infection, and aggressive treatment of suspected organisms.",
author = "O'Dwyer, {P. J.} and Spiers, {A. S D} and S. Marsoni",
year = "1986",
language = "English",
volume = "70",
pages = "1117--1120",
journal = "Cancer Treatment Reports",
issn = "0361-5960",
publisher = "U.S. National Cancer Institute",
number = "9",

}

TY - JOUR

T1 - Association of severe and fatal infections and treatment with pentostatin

AU - O'Dwyer, P. J.

AU - Spiers, A. S D

AU - Marsoni, S.

PY - 1986

Y1 - 1986

N2 - Pentostatin (dCF), an inhibitor of adenosine deaminase, has shown activity in the treatment of several lymphoid malignancies, even in the earliest phase I trials. An analysis of the first 300 patients treated in such trials shows a high incidence of severe infection (8%) during the relatively brief period of treatment. Of 24 patients in whom infection was diagnosed, 17 had no evidence of myelosuppression. The causative organisms included viruses, fungi, and bacteria of both high and low pathogenicity. Two-thirds of the infections were fatal. It is suggested that dCF may cause a syndrome similar to severe combined immunodeficiency during the course of treatment. Patients treated with dCF who show evidence of infection, even in the absence of neutropenia, should receive vigorous and rapid diagnostic evaluation to establish the cause of their infection, and aggressive treatment of suspected organisms.

AB - Pentostatin (dCF), an inhibitor of adenosine deaminase, has shown activity in the treatment of several lymphoid malignancies, even in the earliest phase I trials. An analysis of the first 300 patients treated in such trials shows a high incidence of severe infection (8%) during the relatively brief period of treatment. Of 24 patients in whom infection was diagnosed, 17 had no evidence of myelosuppression. The causative organisms included viruses, fungi, and bacteria of both high and low pathogenicity. Two-thirds of the infections were fatal. It is suggested that dCF may cause a syndrome similar to severe combined immunodeficiency during the course of treatment. Patients treated with dCF who show evidence of infection, even in the absence of neutropenia, should receive vigorous and rapid diagnostic evaluation to establish the cause of their infection, and aggressive treatment of suspected organisms.

UR - http://www.scopus.com/inward/record.url?scp=0022508693&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022508693&partnerID=8YFLogxK

M3 - Article

C2 - 3488805

AN - SCOPUS:0022508693

VL - 70

SP - 1117

EP - 1120

JO - Cancer Treatment Reports

JF - Cancer Treatment Reports

SN - 0361-5960

IS - 9

ER -